Could Antares Pharma Inc (NASDAQ:ATRS) Skyrocket? The Stock Had Too Little Sellers

Investors sentiment increased to 1.74 in 2018 Q4. Its up 0.53, from 1.21 in 2018Q3. It is positive, as 6 investors sold Antares Pharma, Inc. shares while 25 reduced holdings. 24 funds opened positions while 30 raised stakes. 61.54 million shares or 8.31% more from 56.81 million shares in 2018Q3 were reported.
Rhumbline Advisers owns 186,863 shares. Manufacturers Life Insurance Com The reported 104,012 shares or 0% of all its holdings. M&T Bank has 130,000 shares. Hightower Advisors Limited Liability holds 29,235 shares or 0% of its portfolio. Proshare Advisors Ltd Liability Corp holds 0% or 15,209 shares in its portfolio. State Board Of Administration Of Florida Retirement, Florida-based fund reported 59,413 shares. Brown Advisory Limited Liability Corp holds 0.15% or 275,000 shares in its portfolio. Virtu Fin Limited Liability Com holds 0% or 16,601 shares in its portfolio. 10.30 million were reported by Armistice Capital Ltd Limited Liability Company. has 95,044 shares. Prudential has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS). Zurcher Kantonalbank (Zurich Cantonalbank) owns 11,255 shares or 0% of their US portfolio. Jw Asset Management Limited Liability Company invested in 3.85% or 1.92 million shares. Art Limited Liability Corp holds 100,994 shares or 0.02% of its portfolio. Susquehanna Int Llp reported 148,358 shares.

Since October 2, 2018, it had 0 insider buys, and 1 insider sale for $1.52 million activity.

The stock of Antares Pharma Inc (NASDAQ:ATRS) registered a decrease of 0.95% in short interest. ATRS’s total short interest was 8.60 million shares in March as published by FINRA. Its down 0.95% from 8.68M shares, reported previously. With 564,600 shares average volume, it will take short sellers 15 days to cover their ATRS’s short positions. The short interest to Antares Pharma Inc’s float is 6.31%.

The stock increased 0.28% or $0.01 during the last trading session, reaching $3.64. About 826,921 shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 74.65% since March 14, 2018 and is uptrending. It has outperformed by 70.28% the S&P500.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $584.34 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

Antares Pharma, Inc. (NASDAQ:ATRS) Ratings Coverage

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 5 analyst reports since October 2, 2018 according to SRatingsIntel. The company was initiated on Monday, February 25 by Cowen & Co. H.C. Wainwright maintained the shares of ATRS in report on Monday, March 11 with “Buy” rating. Raymond James maintained the stock with “Strong Buy” rating in Monday, March 4 report. Jefferies maintained the shares of ATRS in report on Friday, February 22 with “Buy” rating. The stock of Antares Pharma, Inc. (NASDAQ:ATRS) earned “Strong Buy” rating by Raymond James on Tuesday, October 2.

More notable recent Antares Pharma, Inc. (NASDAQ:ATRS) news were published by: Businesswire.com which released: “Hercules Capital Announces Multiple Outstanding Achievements by Numerous Investment Portfolio Companies – Business Wire” on February 12, 2019, also Seekingalpha.com with their article: “Antares Pharma: Excellent Risk-Reward Profile – Seeking Alpha” published on May 22, 2018, Nasdaq.com published: “AMAG’s Stock Down as Pregnancy Drug Fails in PROLONG Study – Nasdaq” on March 11, 2019. More interesting news about Antares Pharma, Inc. (NASDAQ:ATRS) were released by: Businesswire.com and their article: “Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to Class Action – Business Wire” published on November 09, 2018 as well as Seekingalpha.com‘s news article titled: “Antares Pharma: Proven Business Model Set To Move Much Higher – Seeking Alpha” with publication date: August 20, 2018.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.